Novel antifungal from Viamet selected for NIH rare diseases drug program
Links shared publicly online about this topic.
- 113total visits
Novel antifungal from Viamet selected for NIH rare diseases drug program
North Carolina drug company Viamet will work with the NIH to jointly develop one of Viamet's novel antifungal compounds. Read about what this means for Viamet.
View full resource at medcitynews.com
Tags: Disease and Condition, Drug, National Institutes of Health, disease
Most Recently Shared on July 28, 2011 at 4:20 pm By:
Novel antifungal from Viamet selected for NIH rare diseases drug program http://bit.ly/nv9C31
Advertisement
